Ayala Pharmaceuticals, Inc.
OTC: ADXS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Kenneth A. Berlin
- Employees
- 20
- Headquarters
- Monmouth Junction, United States
- IPO year
- 2020
- Market cap
- $25.7M
- Website
- https://www.ayalapharma.com
Loading ADXS…
Loading profile data…Frequently asked questions about ADXS
What does Ayala Pharmaceuticals, Inc. (ADXS) do?
Ayala Pharmaceuticals, Inc., a clinical-stage oncology firm, focuses on developing and commercializing small molecule therapies for individuals battling rare tumors and aggressive cancers. Its primary drug candidates currently in development include AL102, an oral gamma secretase inhibitor for desmoid tumors, and aspacytarabine (BST-236), an inn...
Where does ADXS trade?
Ayala Pharmaceuticals, Inc. (ADXS) trades on the Other OTC.
What sector is ADXS in?
Ayala Pharmaceuticals, Inc. (ADXS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Ayala Pharmaceuticals, Inc.?
Kenneth A. Berlin is the chief executive officer of Ayala Pharmaceuticals, Inc. (ADXS).
Where is Ayala Pharmaceuticals, Inc. headquartered?
Ayala Pharmaceuticals, Inc. is headquartered in United States.
Does ADXS pay a dividend?
Ayala Pharmaceuticals, Inc. (ADXS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ADXS go public?
Ayala Pharmaceuticals, Inc. (ADXS) completed its initial public offering in 2020.